Company intelligence / Profile preview

Zhejiang Emperor Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Zhejiang Emperor Pharmaceutical is a private Chinese pharmaceutical company specializing in herbal medicines. Its lead product, Grannle Dendrobii (Tiepi Fengdou Granules), is approved in China for the treatment of cough. The company has completed Phase 2 and Phase 3 clinical trials evaluating this product for chronic atrophic gastritis with Qi and Yin deficiency syndrome. The company's focus is on respiratory diseases and gastrointestinal disorders using traditional Chinese medicinal approaches.

Therapeutic areas: GastroenterologyPulmonology
Modalities: Herbal medicineSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Zhejiang Emperor Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Emperor Pharmaceutical.

Explore the full profile